ArticleiScience2026
Nine anthropometric insulin resistance indices predict mortality and life expectancy across glucose states.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the impact of insulin resistance indicators (triglyceride-glucose index, TyG) combined with different obesity metrics on long-term survival rates across varying states of glucose metabolism. In 11,787 U.S. adults aged ≥45 years from NHANES (1999-2018; mortality follow-up through December 31, 2019) and 12,915 participants from CHARLS for external validation, we examined nine TyG-derived indices using glycemic-status-stratified Cox models and flexible dose-response analyses, and assessed their predictive utility and clinical net benefit. The TyG index combined with a body shape index (TyG-ABSI) showed relatively consistent associations with all-cause and cardiovascular mortality and comparatively favorable incremental predictive performance; external validation in CHARLS supported its association with all-cause mortality, although its standalone discriminatory ability was modest. Higher TyG-ABSI was also associated with shorter life expectancy and a larger estimated population-attributable fraction, supporting its potential role in risk stratification across glucose metabolism states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.